The Molecular Biology of Pulmonary Metastasis

Thoracic Surgery Clinics

Volumn 16, Issue 2, 2006, Pages 115-124

  Krishnan, Kartik ^a   Khanna, Chand ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HLA ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; STROMAL CELL DERIVED FACTOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

BREAST CARCINOMA; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; DNA MICROARRAY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOSURVEILLANCE; LUNG METASTASIS; MAMMOGRAPHY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE;

ANIMALS; APOPTOSIS; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM METASTASIS;

EID: 33646586676     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2005.12.003     Document Type: Review

References (82)

1. In: Ries L., Eisner M., Kosary C., et al. (Eds). SEER Cancer Statistics Review, 1975-2002 (2005), National Cancer Institute, Bethesda, (MD)
2. Fidler I.J., and Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (1977) 893-895
3. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
4. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
5. Weigelt B., Hu Z., He X., et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65 (2005) 9155-9188
6. Ramaswamy S., Ross K.N., Lander E.S., et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 33 (2003) 49-54
7. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
8. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
9. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003) 3983-3988
10. Brabletz T., Jung A., Spaderna S., et al. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5 (2005) 744-749
11. Ewing J. Neoplastic Diseases: A Textbook on Tumors. 3rd edition (1928), WB Saunders, Co., Philadelphia
12. Coman D.R., de Long R., and McCutcheon M. Studies on the mechanisms of metastasis; the distribution of tumors in various organs in relation to the distribution of arterial emboli. Cancer Res 11 (1951) 648-651
13. Weigelt B., Wessels L.F., Bosma A.J., et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer 93 (2005) 924-932
14. Weigelt B., Glas A.M., Wessels L.F., et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100 (2003) 15901-15905
15. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
16. Wang J.M., Deng X., Gong W., et al. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220 (1998) 1-17
17. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
18. Li Y.M., Pan Y., Wei Y., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6 (2004) 459-469
19. Murakami T., Maki W., Cardones A.R., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62 (2002) 7328-7334
20. Liotta L.A., Kleinerman J., Catanzaro P., et al. Degradation of basement membrane by murine tumor cells. J Natl Cancer Inst 58 (1977) 1427-1431
21. Puente X.S., Sanchez L.M., Overall C.M., et al. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4 (2003) 544-558
22. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
23. Zucker S., and Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23 (2004) 101-117
24. Wagenaar-Miller R.A., Gorden L., and Matrisian L.M. Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev 23 (2004) 119-135
25. Folgueras A.R., Pendas A.M., Sanchez L.M., et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48 (2004) 411-424
26. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
27. Moore M.J., Hamm J., Dancey J., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3296-3302
28. Albini A., Melchiori A., Santi L., et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83 (1991) 775-779
29. Baker A.H., George S.J., Zaltsman A.B., et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 (1999) 1347-1355
30. Brand K., Baker A.H., Perez-Canto A., et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60 (2000) 5723-5730
31. Aljada I.S., Ramnath N., Donohue K., et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 22 (2004) 3218-3229
32. Zeng Z.S., Cohen A.M., Zhang Z.F., et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1 (1995) 899-906
33. Frisch S.M., and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124 (1994) 619-626
34. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 7 (2002) 247-260
35. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5 (2004) 816-826
36. Parsons J.T., Martin K.H., Slack J.K., et al. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19 (2000) 5606-5613
37. Fukata M., and Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol 2 (2001) 887-897
38. Seftor R.E., Seftor E.A., Gehlsen K.R., et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89 (1992) 1557-1561
39. Zheng D.Q., Woodard A.S., Fornaro M., et al. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59 (1999) 1655-1664
40. Ruoslahti E., and Reed J.C. Anchorage dependence, integrins, and apoptosis. Cell 77 (1994) 477-478
41. Weiner T.M., Liu E.T., Craven R.J., et al. Expression of focal adhesion kinase gene and invasive cancer. Lancet 342 (1993) 1024-1025
42. Beavon I.R. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 36 (2000) 1607-1620
43. McLean G.W., Carragher N.O., Avizienyte E., et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5 (2005) 505-515
44. Pantelouris E.M. Absence of thymus in a mouse mutant. Nature 217 (1968) 370-371
45. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95 (1998) 7556-7561
46. Flanagan S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 8 (1966) 295-309
47. Garrido F., Ruiz-Cabello F., Cabrera T., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18 (1997) 89-95
48. Moretta A., Bottino C., Vitale M., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14 (1996) 619-648
49. Schreiber H., Wu T.H., Nachman J., et al. Immunodominance and tumor escape. Semin Cancer Biol 12 (2002) 25-31
50. Letterio J.J., and Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16 (1998) 137-161
51. Kirkbride K.C., and Blobe G.C. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther 3 (2003) 251-261
52. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999-1005
53. Mocellin S., Mandruzzato S., Bronte V., et al. Part I: Vaccines for solid tumours. Lancet Oncol 5 (2004) 681-689
54. Zhang H., Chua K.S., Guimond M., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11 (2005) 1238-1243
55. Lopez M.V., Adris S.K., Bravo A.I., et al. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J Immunol 175 (2005) 5885-5894
56. Okegawa T., Li Y., Pong R.C., et al. Cell adhesion proteins as tumor suppressors. J Urol 167 (2002) 1836-1843
57. Martin T.A., Harrison G., Mansel R.E., et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46 (2003) 165-186
58. Wielenga V.J., Heider K.H., Offerhaus G.J., et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53 (1993) 4754-4756
59. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 20 (2003) 195-201
60. Franck Z., Footer M., and Bretscher A. Microinjection of villin into cultured cells induces rapid and long-lasting changes in cell morphology but does not inhibit cytokinesis, cell motility, or membrane ruffling. J Cell Biol 111 (1990) 2475-2485
61. Elliott B.E., Meens J.A., SenGupta S.K., et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7 (2005) R365-R373
62. Khanna C., Wan X., Bose S., et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10 (2004) 182-186
63. Yu Y., Khan J., Khanna C., et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10 (2004) 175-181
64. Wan X., Mendoza A., Khanna C., et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65 (2005) 2406-2411
65. Holmgren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1 (1995) 149-153
66. O'Reilly M.S., Holmgren L., Chen C., et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
67. Bayko L., Rak J., Man S., et al. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis 2 (1998) 203-217
68. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 11 (2001) 285-295
69. Farrar J.D., Katz K.H., Windsor J., et al. Cancer dormancy. VII. A regulatory role for CD8 + T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 162 (1999) 2842-2849
70. Aguirre-Ghiso J.A., Estrada Y., Liu D., et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63 (2003) 1684-1695
71. Goodison S., Kawai K., Hihara J., et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9 (2003) 3808-3814
72. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
73. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19 (2000) 4611-4620
74. Rak J., Mitsuhashi Y., Sheehan C., et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60 (2000) 490-498
75. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
76. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
77. Goldman C.K., Kim J., Wong W.L., et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4 (1993) 121-133
78. El-Rayes B.F., and LoRusso P.M. Targeting the epidermal growth factor receptor. Br J Cancer 91 (2004) 418-424
79. Sikder H., Huso D.L., Zhang H., et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 4 (2003) 291-299
80. Alani R.M., Silverthorn C.F., and Orosz K. Tumor angiogenesis in mice and men. Cancer Biol Ther 3 (2004) 498-500
81. Khanna C., and Hunter K. Modeling metastasis in vivo. Carcinogenesis 26 (2005) 513-523
82. Cai Z., Chiu J.F., and He Q.Y. Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics 2 (2004) 152-166